Home Cart Sign in  
Chemical Structure| 1273323-67-3 Chemical Structure| 1273323-67-3

Structure of YLF-466D
CAS No.: 1273323-67-3

Chemical Structure| 1273323-67-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

YLF-466D is an allosteric AMPK activator.

Synonyms: C24

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of YLF-466D

CAS No. :1273323-67-3
Formula : C29H20ClNO3
M.W : 465.93
SMILES Code : O=C(O)C1=CC=CC(CN2C(/C(C3=C2C=CC=C3)=C(C4=CC=C(Cl)C=C4)\C5=CC=CC=C5)=O)=C1
Synonyms :
C24
MDL No. :MFCD28167740
InChI Key :BPBOVHROVFJFAH-CYYJNZCTSA-N
Pubchem ID :51033997

Safety of YLF-466D

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of YLF-466D

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hepatocytes (from AMPK FLOX and AMPK LKO mice) 10 μM 20 hours To confirm whether the inhibitory effect of C24 on lipogenesis depends on AMPK activation, results showed that the inhibitory effect of C24 was abolished in AMPK-deficient hepatocytes. PMC8115652
HepG2 cells 5–40 μM 20 hours To evaluate the effect of C24 on lipogenesis, results showed that C24 dose-dependently inhibited lipogenesis in HepG2 cells. PMC8115652

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
New Zealand rabbits High-fat high-cholesterol diet-induced dyslipidemia model Oral gavage 20, 40, 60 mg/kg Once daily for 4 weeks To evaluate the effect of C24 on dyslipidemia, results showed that C24 dose-dependently reduced plasma TG, TC, and LDL-C levels. PMC8115652

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.21mL

10.73mL

2.15mL

1.07mL

21.46mL

4.29mL

2.15mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories